logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Haiyan Yang

Zhejiang Cancer Hospital
H指数:24
被引数:2,128

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A single-center, randomized, double-blind, positive-controlled, phase IV clinical trial to assess the immunogenicity and safety of adsorbed tetanus toxoid vaccine in individuals aged ≥16 years

一项单中心、随机、双盲、阳性对照的IV期临床试验，旨在评估≥16岁个体接种吸附破伤风类毒素疫苗后的免疫原性和安全性。

Human Immunology
IF2.2
2025-11-140
PRE
Qinghu Guan; Jun Liu; Miaomiao Tang; Qingliang Li; Haiyan Yang; Zeyu Zhang; Shiyi Liu; Xuejuan Wang; Cong Wu; Tian Zeng; Yajie Zhou; Yuanxue Gao; Hu Chen; Yajun Yang; Wei Chen; Shengli Meng; Ruizhi Zhang
Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial
CANCER
IF5.1
2025-01-020
OAAI
Gao, Yan; Huang, Yunhong; Zhang, Qingyuan; Yang, Haiyan; Li, Yufu; Li, Yan; Zhou, Min; Yang, Runxiang; Xu, Bing; Liu, Lihong; Yang, Yu; Peng, Zhigang; Yu, Ding; Zhou, Hui; Zhang, Rongyan; Zhang, Huilai; Qi, Junyuan; Xi, Yaming; Xing, Xiaojing; Wang, Zhao; Jing, Hongmei; Shuang, Yuerong; Zhang, Xiaohong; Ma, Liping; Jin, Hongyan; Lin, Li'e; Li, Chunlei; Xue, Jianfei; Liu, Yanping; Yuan, Jing; Huang, Huiqiang
Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naive (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

HZ-a-018研究（一项Bruton Tyrosine Kinase [BTK]抑制剂）在复发和/或难治性（R/R）中枢神经系统淋巴瘤或初治（TN）中枢神经系统淋巴瘤成年患者中的初步疗效与安全性：HZ-a-018-102研究Ib期联合治疗部分的结果

BLOOD
IF23.1
2024-11-050
PRE
Li, Wenbin; Kang, Zhuang; Chen, Feng; Li, Shenglan; Chen, Xi; Yuan, Xianggui; Yang, Haiyan; Qian, Wenbin; Hu, Miao; Zhang, Yanping; Zhou, Xinglu
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial
JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2024-10-240
OAAI
Li, Zhiming; Jiang, Wenqi; Zhou, Hui; Cen, Hong; Zhang, Mingzhi; Lv, Fangfang; Zhang, Qingyuan; Sun, Xiuhua; Liu, Lihong; Huang, Yunhong; Yang, Haiyan; Gao, Sujun; He, Chuan; Yang, Wei; Li, Wenyu; Yu, Ding; Yang, Yu; Cheng, Ying; Qian, Zhengzi; Xiang, Ying; Guo, Qunyi; Xu, Bing; Song, Yuqin; Zhang, Liling; Lin, Lie; Shen, Jianzhen; Yan, Feng; Liu, Huilan; Zhang, Donghua; Wang, Jishi; Zhou, Min; Zhu, Xiongpeng; Zhang, Weihua; Zhao, Weili; Feng, Ru; Zhang, Xiaohong; Jin, Jie; Zhong, Meizuo; Zhang, Mei; Wang, Jingbo; Jing, Hongmei; Wang, Zhao; Zhao, Hongguo; Zhu, Jun
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study

奥列拉布替尼治疗复发或难治性边缘区淋巴瘤: 2期、多中心、开放标签研究

AMERICAN JOURNAL OF HEMATOLOGY
IF9.9
2023-08-302
PRE
Deng, Lijuan; Li, Zhiming; Zhang, Huilai; Huang, Haiwen; Hu, Jianda; Liu, Lihong; Liu, Ting; Jin, Jie; Zhu, Zunmin; Li, Wenyu; Huang, Zhenqian; Huang, Wenrong; Zhou, Keshu; Yang, Haiyan; Zhang, Mingzhi; Ding, Kaiyang; Zhou, Hui; Hu, Yu; Shuang, Yuerong; Cao, Junning; Gao, Sujun; Li, Dengju; Sun, Zimin; Zhang, Qingyuan; Yi, Shuhua; Ji, Chunyan; Zhang, Liansheng; Hou, Cheng; Du, Yue; Wang, Weige; Zhao, Renbin; Song, Yuqin; Zhu, Jun
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
BLOOD ADVANCES
IF7.1
2023-08-114
OAAI
Bachy, Emmanuel; Savage, Kerry J.; Huang, Huiqiang; Kwong, Yok-Lam; Gritti, Giuseppe; Zhang, Qingyuan; Liberati, Anna Marina; Cao, Junning; Yang, Haiyan; Hao, Siguo; Hu, Jianda; Zhou, Keshu; Petrini, Mario; Russo, Filomena; Zhang, Huilai; Sang, Wei; Ji, Jie; Ferreri, Andres Jose Maria; Damaj, Gandhi Laurent; Liu, Hui; Zhang, Wei; Ke, Xiaoyan; Ghiggi, Chiara; Huang, Sha; Li, Xiaotong; Yao, Hui; Paik, Jason; Noveotny, William; Zhou, Wenxiao; Zhu, Hongji; Zinzani, Pier Luigi
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study

奥列拉布替尼治疗复发或难治性MCL: 1/2期、开放标签、多中心、单臂研究

BLOOD ADVANCES
IF7.1
2023-08-108
OAAI
Deng, Li-Juan; Zhou, Ke-Shu; Liu, Li-Hong; Zhang, Ming-Zhi; Li, Zhi-Ming; Ji, Chun-Yan; Xu, Wei; Liu, Ting; Xu, Bing; Wang, Xin; Gao, Su-Jun; Zhang, Hui-Lai; Hu, Yu; Li, Yan; Cheng, Ying; Yang, Hai-Yan; Cao, Jun-Ning; Zhu, Zun-Min; Hu, Jian-Da; Zhang, Wei; Jing, Hong-Mei; Ding, Kai-Yang; Zhang, Xiang-Yang; Zhao, Ren -Bin; Zhang, Bin; Tian, Ya -Min; Song, Yong-Ping; Song, Yu-Qin; Zhu, Jun
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma

zanubrutinib与orelabrutinib在复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤或复发或难治性套细胞淋巴瘤患者中的疗效间接比较

INVESTIGATIONAL NEW DRUGS
IF2.7
2023-07-081
OAAI
Song, Yuqin; Zhou, Keshu; Yang, Shenmiao; Hu, Jianda; Zou, Dehui; Gao, Sujun; Pan, Ling; Wang, Tingyu; Yang, Haiyan; Zhang, Huilai; Zhou, Daobin; Ji, Jie; Xu, Wei; Feng, Ru; Jin, Jie; Lv, Fangfang; Huang, Haiwen; Fan, Xiaosi; Xu, Sheng; Zhu, Jun

研究方向

暂未获取到该数据
H
Huilai Zhang
H 指数:37论文数:375被引数:5,125
J
Jun Zhu
H 指数:40论文数:324被引数:7,423
J
Jianda Hu
H 指数:36论文数:475被引数:6,558
X
Xiaowu Dong
H 指数:35论文数:236被引数:4,648
L
Liling Zhang
H 指数:42论文数:325被引数:6,555
W
Wenyu Li
H 指数:21论文数:175被引数:1,810
Y
Yuqin Song
H 指数:37论文数:355被引数:6,250
D
Dehui Zou
H 指数:29论文数:512被引数:3,132
K
Keshu Zhou
H 指数:23论文数:352被引数:2,404
Z
Zhiming Li
H 指数:29论文数:351被引数:3,414